LaTese Briggs
Showing 1–4 of 4 transcripts.
- Milken Institute1h 0m
Philanthropy and Democracy in the 21st-Century
LaTese Briggs, Chuck Harris, George Pavlov, Rob Reich, Amy Smith
Moderator Latisse Briggs hosted a panel featuring Chuck Harris, George Pavlov, Rob Reich, and Amy Smith to dissect the tension between rising inequality and philanthropic capital deployment strategies. The speakers critiqued the "dead hand" of perpetual wealth and the plutocratic nature of tax deductions, advocating instead for time-limited funding cycles, radical transparency, and collaborative "collusion for good" to replace isolated market-style philanthropy. Ultimately, the group consensus emphasized that private capital must shift from temporary fixes to scalable, evidence-based interventions that influence government priorities while respecting democratic accountability.
- Milken Institute58 min
From Stigma to Treatment: Tackling the Global Mental Health Crisis
LaTese Briggs, Lynne Goldberg, Annalisa Jenkins, Elie Karam, Colin Lawlor
A global panel of experts, including Dr. Lattice Briggs, Annalisa Jenkins, and Colin Lawler, highlights a rising mental health crisis driven by chronic stress, sleep deprivation, and systemic barriers that threaten to cost the global economy $16 trillion by 2030. The discussion identifies ignorance, stigma, and an overreliance on institutional "sick care" as primary obstacles, while advocating for a shift toward community-based prevention, digital interventions, and emerging pharmaceuticals like psilocybin. Speakers emphasize that resolving this crisis requires treating mental health as a human rights issue and integrating preventative care into existing community infrastructure to sustain the future global workforce.
- Milken Institute1h 5m
Alzheimer's Disease: Rewriting the Playbook
LaTese Briggs, Michela Gallagher, Todd Rainwater, Lauren Miller Rogen, Garen Staglin, Garen King Jr., Daniel Arbus, Elizabeth Scharf, Amir, Mark Reuthmeyer
Leading scientists and philanthropists convened to address the projected surge in Alzheimer's prevalence and its looming $1.1 trillion economic impact by 2050, shifting research focus from the failed amyloid hypothesis to tau-targeted interventions and early prodromal treatment. The panel highlighted strategic initiatives such as the TAO Consortium's $100 million investment in tauopathies, the proposed $10 billion global social impact bond, and new collaborative models designed to accelerate FDA approval through consortium-based data sharing. By combining precision medicine, open science, and stigma-reduction advocacy, these stakeholders aim to de-risk early-stage development and attract pharmaceutical investment to prevent a global health crisis.
- Milken Institute1h 1m
Supercharge the Search for Cures: Medical Philanthropists Reinvent Giving to Get Results
LaTese Briggs, Debra Black, Cindy L. Citrone, Joyce Keller, Melissa Stevens, Rob Citron
A panel of leaders from the Melanoma Research Alliance, 33 Foundation, and Gilbert Family Foundation discussed a strategic sector shift from reactive check-writing to active venture philanthropy that leverages flexible capital to fill the translational research gap. These institutions demonstrated high-impact outcomes, such as funding all 11 FDA-approved melanoma therapies and developing a non-profit venture fund to accelerate breast cancer treatments, while also employing non-cash assets like sports partnerships to drive systemic organ donation reforms. By addressing structural barriers including the nonprofit consolidation of small entities and the medical device "valley of death," the experts advocated for patient-centric infrastructure investments and deep, data-driven engagement models to maximize scientific returns.